Viridian Therapeutics
VRDN
105 hedge funds and large institutions have $778M invested in Viridian Therapeutics in 2022 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 51 increasing their positions, 14 reducing their positions, and 10 closing their positions.
456% more call options, than puts
Call options by funds: $3.62M | Put options by funds: $652K
264% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 14
210% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 10
138% more capital invested
Capital invested by funds: $328M → $778M (+$451M)
67% more funds holding in top 10
Funds holding in top 10: 6 → 10 (+4)
25% more funds holding
Funds holding: 84 → 105 (+21)
1.73% less ownership
Funds ownership: 101.4% → 99.68% (-1.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
+$19M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
+$18M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$15.8M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$14.4M |
| 5 |
State Street
Boston,
Massachusetts
|
+$13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$14.8M |
| 2 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$11.3M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$9.05M |
| 4 |
Millennium Management
New York
|
-$6.54M |
| 5 |
ABG
Ally Bridge Group
New York
|
-$5.74M |
VRDN Hedge Fund Activity: Q3 2022 in Review
105 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q3 2022, worth a combined $778M — up 138% from $328M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new VRDN positions and 10 closed out — a net gain of 21 holders — while 51 added to existing stakes and 14 trimmed.
The largest buyer was Commodore Capital, adding an estimated $19M. The largest seller was Soleus Capital Management, cutting an estimated $14.8M.
- 105 institutional investors held Viridian Therapeutics (VRDN) as of Q3 2022, up from 84 in Q2 2022.
- Funds reported $778M of Viridian Therapeutics stock for Q3 2022, up 138% quarter-over-quarter.
- 31 funds opened new Viridian Therapeutics positions in Q3 2022 and 10 closed out, a net change of +21 holders.
- The largest Viridian Therapeutics buyer in Q3 2022 was Commodore Capital, an estimated $19M added.
- The largest Viridian Therapeutics seller in Q3 2022 was Soleus Capital Management, an estimated $14.8M sold.
Based on aggregated 13F filings for Q3 2022.